Literature DB >> 23335569

Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria?

William J Taylor1, Melanie Brown, Opetaia Aati, Mark Weatherall, Nicola Dalbeth.   

Abstract

OBJECTIVE: To determine patient-derived weights or prioritization for core outcome domains in chronic gout clinical studies.
METHODS: Three patient groups participated in a conjoint decision-making exercise using 1000Minds software, which asked participants to make repeated judgments regarding which of 2 hypothetical patients with gout represented the best response to treatment. Each scenario compared 2 patients on the basis of change in 2 of 5 core outcome domains at a time. Agreement of 80% of the group was required to answer each scenario. Re-voting was performed once after discussion in instances of disagreement.
RESULTS: The relative importance accorded to each outcome domain was different across the 3 groups of patients. There was some consistency that tophi was the least or second to least important outcome domain for every group and pain between attacks was ranked in the bottom third of priority for all groups. Gout attacks were ranked as the second or third most important domain in each group. However, the relative importance of serum urate (SUA) and activity limitations was quite different among the 3 groups, with 1 group ranking SUA as the most important outcome and 1 group ranking it as the second to least important outcome.
CONCLUSION: Despite some consistency in the relative value of some outcome domains for chronic gout studies, there is sufficient disagreement in the relative importance of other domains of outcome to challenge the validity of constructing a composite index of response that would be applicable to most gout patients.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23335569     DOI: 10.1002/acr.21955

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  8 in total

Review 1.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

2.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

3.  Concurrent validity of provisional remission criteria for gout: a dual-energy CT study.

Authors:  Nicola Dalbeth; Christopher Frampton; Maple Fung; Scott Baumgartner; Savvas Nicolaou; Hyon K Choi
Journal:  Arthritis Res Ther       Date:  2019-06-21       Impact factor: 5.156

4.  Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1.

Authors:  Tiago Ribeiro; Audrey Abad; Brian M Feldman
Journal:  Res Pract Thromb Haemost       Date:  2019-05-20

5.  Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout.

Authors:  Naomi Schlesinger; N Lawrence Edwards; Puja P Khanna; Anthony E Yeo; Peter E Lipsky
Journal:  ACR Open Rheumatol       Date:  2019-05-23

6.  Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline.

Authors:  Jasvinder A Singh; Tuhina Neogi; John D FitzGerald
Journal:  ACR Open Rheumatol       Date:  2020-11-22

7.  2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Authors:  Rohit Aggarwal; Lisa G Rider; Nicolino Ruperto; Nastaran Bayat; Brian Erman; Brian M Feldman; Chester V Oddis; Anthony A Amato; Hector Chinoy; Robert G Cooper; Maryam Dastmalchi; David Fiorentino; David Isenberg; James D Katz; Andrew Mammen; Marianne de Visser; Steven R Ytterberg; Ingrid E Lundberg; Lorinda Chung; Katalin Danko; Ignacio García-De la Torre; Yeong Wook Song; Luca Villa; Mariangela Rinaldi; Howard Rockette; Peter A Lachenbruch; Frederick W Miller; Jiri Vencovsky
Journal:  Ann Rheum Dis       Date:  2017-05       Impact factor: 19.103

8.  Development and First Validation of a Disease Activity Score for Gout.

Authors:  Carlo A Scirè; Greta Carrara; Cinzia Viroli; Marco A Cimmino; William J Taylor; Maria Manara; Marcello Govoni; Fausto Salaffi; Leonardo Punzi; Carlomaurizio Montecucco; Marco Matucci-Cerinic; Giovanni Minisola
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-09-06       Impact factor: 4.794

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.